2076975 2077203
최종편집 2024-05-23 08:27 (목)
Astellas’ urothelial cancer treatment lands in Korea
상태바
Astellas’ urothelial cancer treatment lands in Korea
  • Hyeokgi Lee, Newsmp
  • 승인 2023.03.11 19:39
  • 댓글 0
이 기사를 공유합니다

Provide treatment opportunities for patients with advanced or metastatic urothelial cancer

[Newsmp] The Ministry of Food and Drug Safety (MFDS) said it has granted the Korea Astellas’ rare drug Padcev (enfortumab vedotin-ejfv), a treatment for urothelial cancer, on Friday.

Padcev is an antibody-drug conjugate (ADC) that targets the protein Nectin-4, which is highly expressed on the surface of urothelial cancer cells.

The antibody acts like a homing signal, inducing the chemo drug, monomethyl auristatin E, directly to bladder cancer cells with a protein called Nectin-4 on them and killing them.

The approved indication is for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with PD-1 or PD-L1 inhibitors and platinum-based chemotherapy.

The MFDS stated that this approval will provide new treatment options for patients with advanced or metastatic urothelial cancer.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.